WallStSmart

Advanced Biomed Inc. Common Stock (ADVB)vsIQVIA Holdings Inc (IQV)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

IQV leads profitability with a 8.3% profit margin vs 0.0%. ADVB trades at a lower P/E of 1.2x. IQV earns a higher WallStSmart Score of 72/100 (B).

ADVB

Hold

36

out of 100

Grade: F

Growth: 4.3Profit: 5.0Value: 8.3Quality: 6.0
Piotroski: 3/9

IQV

Strong Buy

72

out of 100

Grade: B

Growth: 6.0Profit: 7.0Value: 10.0Quality: 4.3
Piotroski: 4/9Altman Z: 1.33
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

ADVBUndervalued (+99.0%)

Margin of Safety

+99.0%

Fair Value

$23.94

Current Price

$4.28

$19.66 discount

UndervaluedFair: $23.94Overvalued
IQVUndervalued (+49.1%)

Margin of Safety

+49.1%

Fair Value

$348.46

Current Price

$165.64

$182.82 discount

UndervaluedFair: $348.46Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ADVB3 strengths · Avg: 10.0/10
P/E RatioValuation
1.2x10/10

Attractively priced relative to earnings

Price/BookValuation
0.5x10/10

Reasonable price relative to book value

Return on EquityProfitability
80.2%10/10

Every $100 of equity generates 80 in profit

IQV3 strengths · Avg: 8.3/10
Return on EquityProfitability
21.4%9/10

Every $100 of equity generates 21 in profit

PEG RatioValuation
0.978/10

Growing faster than its price suggests

EPS GrowthGrowth
23.6%8/10

Earnings expanding 23.6% YoY

Areas to Watch

ADVB4 concerns · Avg: 3.5/10
Revenue GrowthGrowth
0.0%4/10

0.0% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$5.66M3/10

Smaller company, higher risk/reward

Profit MarginProfitability
0.0%3/10

0.0% margin — thin

IQV1 concerns · Avg: 2.0/10
Altman Z-ScoreHealth
1.332/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ADVB

The strongest argument for ADVB centers on P/E Ratio, Price/Book, Return on Equity.

Bull Case : IQV

The strongest argument for IQV centers on Return on Equity, PEG Ratio, EPS Growth. Revenue growth of 10.3% demonstrates continued momentum. PEG of 0.97 suggests the stock is reasonably priced for its growth.

Bear Case : ADVB

The primary concerns for ADVB are Revenue Growth, EPS Growth, Market Cap.

Bear Case : IQV

The primary concerns for IQV are Altman Z-Score.

Key Dynamics to Monitor

IQV is growing revenue faster at 10.3% — sustainability is the question.

IQV generates stronger free cash flow (561M), providing more financial flexibility.

Monitor DIAGNOSTICS & RESEARCH industry trends, competitive dynamics, and regulatory changes.

Bottom Line

IQV scores higher overall (72/100 vs 36/100) and 10.3% revenue growth. ADVB offers better value entry with a 99.0% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Advanced Biomed Inc. Common Stock

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Advanced Biomed Inc., an investment holding company, engages in the research and development of microfluidic biochip technologies and provides them for precision oncology detection, diagnosis, and treatment in Taiwan. The company is headquartered in New York, New York.

IQVIA Holdings Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

IQVIA, formerly Quintiles and IMS Health, Inc., is an American multinational company serving the combined industries of health information technology and clinical research. It is a provider of biopharmaceutical development and commercial outsourcing services, focused primarily on Phase I-IV clinical trials and associated laboratory and analytical services, including consulting services.

Want to dig deeper into these stocks?